Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Daemen A; Wolf DM; Korkola JE; Griffith OL; Frankum JR; Brough R; Jakkula LR; Wang NJ; Natrajan R; Reis-Filho JS; Lord CJ; Ashworth A; Spellman PT; Gray JW; van't Veer LJ; Breast Cancer Research And Treatment, 2012, vol. 135, issue 2, p 505, ISSN 15737217. ISBN 15737217.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef